Search This Blog

Thursday, November 9, 2023

GoodRx cuts outlook

 “We are guiding to fourth quarter revenue and Adjusted Revenue in the range of $188 million to $194 million, representing 2%-5% year-over-year growth, and Adjusted EBITDA Margin in the mid-to-high twenty-percent range,” said Karsten Voermann, Chief Financial Officer. “While we are continuing to refine our views on 2024, including assessing the uptake in new initiatives like our integrated savings programs, we feel good about the business growing next year at a roughly similar rate to the growth rate implied in the 4Q23 guide, and we expect our 2024 Adjusted EBITDA Margin6 to meet or exceed 4Q23.”

https://www.businesswire.com/news/home/20231109040388/en/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.